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Two alternatively spliced forms of the human protein tyrosine
phosphatase TCPTP (T-cell protein tyrosine phosphatase) exist:
a 48 kDa form that is targeted to the endoplasmic reticulum
(TC48) and a shorter 45 kDa form that is targeted to the
nucleus (TC45). In this study we have identified Ser-304 (Phe301-
Asp-His-Ser304-Pro-Asn-Lys307) as a major TCPTP phosphory-
lation site and demonstrate that TC45, but not TC48, is phos-
phorylated on this site in vivo. Phosphorylation of TC45 on
Ser-304 was cell cycle-dependent, and increased as cells pro-
gressed from G2 into mitosis, but subsided upon mitotic exit. Ser-
304 phosphorylation was increased when cells were arrested in
mitosis by microtubule poisons such as nocodazole, but remained
unaltered when cells were arrested at the G2/M checkpoint by
adriamycin. Phosphorylation of Ser-304 did not alter significantly
the phosphatase activity or the protein stability of TC45, and had
no apparent effect on TC45 localization. Ser-304 phosphorylation
was ablated when cells were treated with the CDK (cyclin-
dependent protein kinase) inhibitors roscovitine or SU9516,
but remained unaltered when ERK1/2 activation was inhibited
with the MEK (mitogen-activated protein kinase/extracellular-
signal-regulated kinase kinase) inhibitor PD98059. In addition,
recombinant CDKs, but not the Polo-like kinase Plk1, phos-
phorylated Ser-304 in vitro. Our studies identify Ser-304 as a
major phosphorylation site in human TCPTP, and the TC45
variant as a novel mitotic CDK substrate.
Key words: alternative splicing and phosphorylation, cell cycle,
cyclin-dependent protein kinase (CDK), mitosis, protein tyrosine
phosphatase, TC45.
INTRODUCTION
PTPs (protein tyrosine phosphatases) catalyse the dephosphoryla-
tion of tyrosine-phosphorylated proteins and regulate signalling
events that control fundamental cellular processes, such as
growth, proliferation, differentiation, migration and survival [1].
Although the human genome encodes approximately 100 PTP
genes [1,2], many of these genes can be alternatively spliced to
generate structurally distinct enzymes with different subcellular
localizations [1]. It is becoming increasingly apparent that, for
many signalling proteins, alternatively spliced gene products
can have unique biological properties [3]. Hence the number of
functionally distinct PTPs may be significantly greater than the
number of PTP genes identified in the human genome.
Human TCPTP (T-cell PTP) is an intracellular non-receptor
tyrosine-specific phosphatase that is expressed ubiquitously at
all stages of mammalian development [4]. TCPTP was the first
PTP to be cloned, and one of the first PTP transcripts shown to
be alternatively spliced [4–7]. TCPTP mRNA can be alternatively
spliced to generate two TCPTP variants: a 48 kDa protein (TC48)
that is targeted to the endoplasmic reticulum by a hydrophobic
C-terminus, and a shorter 45 kDa form (TC45) that lacks the
hydrophobic C-terminus and is targeted to the nucleus by a
Abbreviations used: CDK, cyclin-dependent protein kinase; DMEM, Dulbecco’s modified Eagle’s medium; DTT, dithiothreitol; EGF, epidermal growth
factor; ERK, extracellular-signal-regulated kinase; FBS, fetal bovine serum; HEK, human embryonic kidney; MALDI-TOF, matrix-assisted laser-desorption
ionization–time-of-flight; MAPK, mitogen-activated protein kinase; MBP, myelin basic protein; PTP, protein tyrosine phosphatase; RCML, reduced
carboxyamidomethylated and maleylated lysozyme; STAT, signal transducer and activator of transcription; TCPTP, T-cell protein tyrosine phosphatase;
TC45 and TC48, TCPTP variants of 45 and 48 kDa respectively, formed by alternative splicing; TFA, trifluoroacetic acid.
1 These authors contributed equally to this work.
2 Present address: Peter MacCallum Cancer Institute, East Melbourne, Victoria 3002, Australia.
3 Present address: The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3050, Australia.
4 Present address: St. Vincent’s Institute of Medical Research, Melbourne, Victoria 3065, Australia.
5 To whom correspondence should be addressed (e-mail Tony.Tiganis@med.monash.edu.au).
bipartite nuclear localization sequence [4,7–11]. Despite TC45
having an apparent exclusively nuclear localization in resting
cells, TC45 can shuttle between the nuclear and cytoplasmic
environments [12] and gain access to cytoplasmic substrates, such
as the EGF (epidermal growth factor) receptor [13,14], the insulin
receptor [15], the adaptor protein p52Shc [14] and JAKs (Janus
protein tyrosine kinases) [16], thereby regulating mitogen/growth
factor- and cytokine-induced signalling [13,14,16,17]. To date,
STATs (signal transducer and activators of transcription) such
as STAT1 are the only known nuclear substrates for TC45 [18,19].
TCPTP may also regulate the progression of cells through the G1
phase of the cell cycle [20,21], but the molecular mechanism by
which this occurs is not known.
Despite TC48 and TC45 having identical catalytic domains and
recognizing common substrates, such as the EGF receptor [14]
and the insulin receptor [15], several lines of evidence indicate
that the two phosphatases might also have distinct substrates and
divergent cellular roles. Utilizing substrate-trapping mutants, we
have shown previously that TC45, but not TC48, recognizes the
tyrosine-phosphorylated adaptor protein p52Shc as well as two
other unidentified substrates in response to EGF stimulation [14].
Moreover, even though both phosphatases can dephosphorylate
the EGF receptor in a cellular context, only TC45 suppresses EGF
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receptor-mediated protein kinase B/Akt signalling [13], whereas
others have reported that an overexpressed substrate-trapping
mutant of TC48, but not TC45, suppresses tumour cell adhesion
and anchorage-independent growth [22]. Taken together, such
observations suggest that TC45 and TC48 can serve as func-
tionally distinct PTPs in vivo.
In the present paper, we demonstrate for the first time that
endogenous TC45, but not the endoplasmic reticulum-localized
TC48, is phosphorylated on Ser-304. We report that Ser-304
phosphorylation occurs primarily during mitosis, and may be me-
diated by CDKs (cyclin-dependent protein kinases). Our studies
suggest that the alternatively spliced forms of TCPTP may be
phosphorylated differentially by CDKs in mitosis, and may thus
have distinct roles in cellular division.
MATERIALS AND METHODS
Materials
PD98059, calyculin A, nocodazole, thymidine, roscovitine and
Pansorbin were purchased from Calbiochem Oncogene Research
Products (Cambridge, MA, U.S.A.); anisomycin and propidium
iodide were from Sigma (St, Louis, MO, U.S.A.); EGF and
monoclonal anti-(cyclin B1) antibody were from BD Biosciences
(Bedford, MA, U.S.A.); monoclonal pan-actin antibody was
from NeoMarkers (Fremont, CA, U.S.A.); a polyclonal antibody
against phospho-ERK (extracellular-signal-regulated kinase)
1/2 was from Promega (Madison, WI, U.S.A.); [32P]Pi was
from Amersham Biosciences (Little Chalfont, Bucks., U.K.);
doxorubicin hydrochloride (adriamycin) and Trans35S-LabelTM
were from ICN Biomedicals (Irvive, CA, U.S.A.). We are grateful
to M. Weber (University of Virginia, Charlottesville, VA, U.S.A.)
for the monoclonal anti-ERK2 antibody 1B3B9, and to E. A. Nigg
(Max Planck Institute of Biochemistry, Martinsried, Germany)
for the purified recombinant human Polo-like kinase Plk1.
The monoclonal anti-TCPTP antibody CF4 has been described
previously [14].
Plasmid constructs
TC45-pMT2, TC45-pCG, pET-GST and pET-TC45 have been
described previously [12,23]. Two rounds of PCR were under-
taken to generate the Ser-304 to Ala or Glu phosphorylation site
mutants using recombinant Taq DNA polymerase (Invitrogen,
Carlsbad, CA, U.S.A.). In the first round, TC45-pBluescript II
KS [10] was used as a template to generate two overlapping PCR
products encompassing the 5′ and 3′ ends of the TC45 cDNA. The
PCR product encompassing the 3′ end of the TC45 cDNA incor-
porated the mutation for converting Ser-304 into either Ala or
Glu; 5′-end PCR products were generated using 5′-GGCTCCCC-
TGCAGATGCCCACCACCATCGAGCGGGAG-3′ and 5′-ATG-
ATCAAAGGCAGGAGATAA-3′, and 3′-end PCR products were
generated with 5′-CGCCGCCTCGAGTTAGGTGTCTGTCAA-
TCTTGGCCT-3′ and 5′-CCTGCCTTTGATCATGCTCCAAAC-
AAAATAATGAC-3′ (for mutating Ser-304 to Ala) or 5′-CCT-
GCCTTTGATCATGAGCCAAACAAAATAATGAC-3′ (for mu-
tating Ser-304 to Glu). For the second round of PCR, a mixture
(approx. 1:1 molar ratio) of the 5′- and 3′-end first-round PCR pro-
ducts was utilized as template to generate the full-length TC45
mutant cDNAs. The oligonucleotides incorporated a PstI site
immediately 5′ to the initiating codon (5′-GGCTCCCCTGCA-
GATGCCCACCACCATCGAGCGGGAG-3′) and a XhoI site
immediately 3′ to the terminating codon (5′-CGCCGCCTCGA-
GTTAGGTGTCTGTCAATCTTGGCCT-3′). PstI/Xho1-digested
second-round PCR products were cloned into the same site of the
mammalian expression vector pMT2.
The TC45-S304A-pCG and TC45-S304E-pCG constructs were
generated by PCR using Platinum Pfx DNA polymerase (Invi-
trogen) and the TC45-S304A-pMT2 and TC45-S304E-pMT2
constructs as templates respectively. The 5′ oligonucleotide
used was 5′-GGCTCCCACTAGTATGCCCACCACCATCGAG-
CGGGAG-3′ and the 3′ oligonucleotide was 5′-CCCAGTCATG-
GATCCTTAGGTGTCTGTCAATCTTGGCCT-3′. The oligonuc-
leotides incorporated an SpeI site immediately 5′ to the initi-
ating codons and a BamHI site immediately 3′ to the termination
codons. The SpeI/BamHI-digested PCR product was cloned into
the XbaI/BamHI site of the mammalian expression vector pCG.
pET-TC45(1–349) and pET-TC45(1–349)S304E bacterial exp-
ression constructs were generated by PCR using Platinum Pfx
DNA polymerase and the TC45-pMT2 and TC45-S304E-pMT2
constructs as templates respectively. The 5′ oligonucleotide
used was 5′-GGCTCCCGGATCCATGCCCACCACCATCGA-
GCGGGAG-3′, and incorporated a BamHI site immediately 5′
of the initiating methionine; the 3′ oligonucleotide was 5′-A-
GCTTACTTAAGAATATCTCGTGAGAGTGACAAGAGGAG-
3′, and incorporated a TAA stop codon followed by an EcoRI site
immediately after the codon for residue 349. The PCR products
were digested with BamHI/EcoRI and cloned into the same
sites of pET-GST to generate pET-GST-TC45(1–349) and pET-
GST-TC45(1–349)S304E. The NcoI/EcoRI fragment from
pET-TC45 was then replaced with the same fragment from ei-
ther pET-GST-TC45(1–349) or pET-GST-TC45(1–349)S304E to
generate pET-TC45(1–349) and pET-TC45(1–349)S304E res-
pectively.
The structures of all constructs generated were confirmed by
restriction endonuclease analysis, and the fidelity of the cloned
cDNAs was confirmed by sequencing.
Cell culture, transfections, cell-cycle synchronization
and flow cytometry
HEK (human embryonic kidney) 293, HeLa cervical adenoca-
rcinoma, U2OS osteosarcoma, and monkey CV1 and COS1 cells
were cultured at 37 ◦C and 5%CO2 in DMEM (Dulbecco’s mod-
ified Eagle’s medium) containing 10% (v/v) FBS (fetal bovine
serum), 100 units/ml penicillin and 100 µg/ml streptomycin.
Where indicated, cells were serum-starved for 20–24 h in DMEM
containing 0.1% (v/v) FBS plus antibiotics.
COS1 cells were transfected by the calcium phosphate pre-
cipitation method as described previously [14], whereas HeLa
cells were transfected with Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s instructions. Where indicated,
HEK293, CV1 and U2OS cells were electroporated at 975 mM
and 200 V as described previously [13]. For cell cycle syn-
chronization, cells were arrested in S-phase in the presence
of 2 mM thymidine for 20 h and then washed with PBS and
released in DMEM plus 10% (v/v) FBS. To arrest cells in
mitosis, cells were treated for 20 h with 100 ng/ml nocodazole.
FACS was performed using propidium iodide-stained cells and
a FACSCalibur flow cytometer (Becton Dickinson).
Metabolic labelling and TCPTP immunoprecipitation
COS1 cells were electroporated as described previously [13] with
20 µg of TC45-pMT2. At 36 h post-transfection, the cells were
washed twice with phosphate-free DMEM and then incubated
in phosphate-free DMEM for 60 min. Cells were labelled with
1.5 mCi of [32P]Pi per 10 cm dish for 5 h at 37 ◦C. Labelled cells
were lysed in IP lysis buffer [50 mM Tris, pH 7.5, 1% (w/v)
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Nonidet P-40, 150 mM NaCl, 50 mM NaF, leupeptin (5 µg/ml),
pepstatin (1 µg/ml), 1 mM benzamidine and 2 mM PMSF] plus
1 µM okadaic acid, and precleared with 0.1 ml of Pansorbin for
30 min at 4 ◦C. Precleared lysates were centrifuged (12 000 g
for 10 min at 4 ◦C), and TCPTP was immunoprecipitated from
the supernatant with the monoclonal anti-TCPTP antibody CF4
as described previously [14].
Reduction, alkylation, tryptic digestion, and phosphopeptide
extraction and purification
The 32P-labelled immunoprecipitated TCPTP was resuspended
in 3 × Laemmli sample buffer plus 10 mM DTT (dithiothreitol)
and boiled for 5 min before being cooled to room temperature;
acrylamide was then added to a final concentration of 1% (w/v).
Alkylation of the denatured and reduced TCPTP was allowed to
proceed for 30 min at room temperature and the immunopre-
cipitates were resolved by SDS/PAGE. After staining with
Coomassie Blue, the gel slice containing the immunoprecipitated
TCPTP was destained, dried and then rehydrated in the presence
of trypsin. Digestions were allowed to proceed overnight at
37 ◦C, and tryptic peptides were eluted with three sequential
30 min washes with 2% (v/v) TFA (trifluoroacetic acid), 0.1%
TFA with 30% (v/v) acetonitrile, and 0.1% TFA with 60%
(v/v) acetonitrile, as described previously [24,25]. The combined
extracts were dried and desalted, and the phosphopeptides
were either analysed by phosphopeptide mapping or separated
by reverse-phase C18 chromatography (300 Å, 5 µm, 1 mm ×
250 mm) using the Amersham Biosciences SMART system
(60 min; linear 0–80% acetonitrile gradient in 0.1% TFA at
50 µl/min) for MALDI-TOF (matrix-assisted laser-desorption
ionization–time-of-flight) MS analysis as described previously
[24–26]. Fractions containing 32P-labelled phosphopeptides were
identified by Cerenkov counting.
[32P]Phosphopeptide mapping
Phosphopeptides were separated in two dimensions on thin-layer
cellulose plates by high-voltage electrophoresis at pH 1.9 [pH
1.9 buffer: 50 ml of formic acid (88%, w/v), 156 ml of glacial
acetic acid, and deionized water to 2 litres] in the first dimension
and ascending phosphochromatography in the second dimension
as described previously [24,25]. [32P]Phosphopeptides were
visualized on a PhosphorImager using Image-Quant software
(Molecular Dynamics).
Phosphate-release sequencing
Reverse-phase chromatography fractions containing [32P]phos-
phopeptides were subjected to [32P]phosphopeptide mapping
on thin-layer cellulose plates [26]. [32P]Phosphopeptides were
then recovered from cellulose in pH 1.9 buffer and attached
covalently to a SequelonTM-AA membrane according to the
manufacturer’s instructions (Millipore, Milford, MA, U.S.A.).
Covalently attached [32P]phosphopeptides were sequenced on
a Hewlett Packard G100A protein sequencer as described pre-
viously [24], with extracted cycles diverted to a fraction collector
and fractions spotted on to cellulose plates and quantified on a
PhosphorImager using Image-Quant software.
Phosphoamino acid analysis
[32P]Phosphopeptides separated by phosphopeptide mapping
were recovered from cellulose in pH 1.9 buffer and hydrolysed in
5.7 M HCl at 110 ◦C for 60 min. 32P-labelled phosphoamino acids
were dried and resuspended in pH 1.9 buffer, and then separated
on thin-layer cellulose plates by high-voltage electrophoresis at
pH 3.5 with internal phosphoamino acid standards as described
previously [26].
MALDI-TOF MS
Tryptic peptides were spotted on to the sample stage with α-cyano-
4-hydroxycinnamic acid, and masses were analysed using a linear
Voyager DE (PerSeptive Biosystems) MALDI-TOF instrument
running in delayed extraction mode.
SDS/PAGE and immunoblotting
Unless otherwise indicated, proteins were resolved on 7.3 cm
long SDS/PAGE (10% polyacrylamide) gels using the Laemmli
discontinuous buffer system [27] and the Bio-Rad (Hercules, CA,
U.S.A.) Mini-PROTEAN® II electrophoresis unit according to the
manufacturer’s instructions. For resolving the dephosphorylated
and Ser-304 phosphorylated forms of TC45, proteins were
resolved on 16 cm long SDS/PAGE (10%) gels using the Bio-
Rad Protean II electrophoresis unit; proteins were electrophoresed
until the 50 kDa protein standard (Bio-Rad Precision Protein
Standards, prestained) was approx. 2 cm from the bottom of the
gel. Resolved proteins were transferred on to an ImmobilonTM-
P transfer membrane (Millipore) using a Bio-Rad Trans-Blot
SD semi-dry electrophoretic transfer apparatus according to
the manufacturer’s instructions, and immunoblotted with the
indicated antibodies as described previously [14]. All blots were
developed using enhanced chemiluminescence (Amersham Life
Sciences, Cleveland, OH, U.S.A.).
Microscopy
For immunofluorescence studies, cells on glass coverslips were
fixed with 3.2% (v/v) paraformaldehyde in PBS and processed as
described previously [14] using the monoclonal anti-TCPTP
antibody CF4, either on its own or in combination with a poly-
clonal antibody specific for the protein phosphorylated on Ser-
304 (see Supplementary Figure 1 at http://www.BiochemJ.org/
bj/380/bj3800939add.htm). Alternatively, cells were stained
with polyclonal anti-TCPTP 159 antibodies in combination with
the monoclonal anti-(cyclin B1) antibody. Alexa Fluor 488 or
568 goat anti-mouse or anti-rabbit IgGs were used as secondary
antibodies (Molecular Probes, Eugene, OR, U.S.A.). For staining
of DNA, cells were incubated with 5 µg/ml RNAase (Roche
Diagnostics, Indianapolis, IN, U.S.A.) in PBS for 30 min, incu-
bated with either propidium iodide or TOTO-3 (Molecular
Probes) in PBS containing RNAase for 15 min, and then washed
extensively with PBS. Where indicated, nuclei were visualized
with Hoechst stain. Coverslips were mounted on to glass
slides in DAKO® fluorescent mounting medium (DAKO Corp.,
Carpinteria, CA, U.S.A.), and immunofluorescence was visu-
alized on an Olympus BX60 microscope or a Bio-Rad MRC 1024
confocal microscope.
Protein kinase and phosphatase assays
CDK assays
For assessing CDK-mediated phosphorylation of Ser-304 in vitro,
recombinant TCPTP-(1–349) and the corresponding Ser-304
phosphorylation site mutant [TCPTP-(1–349)S304E] were
utilized rather than full-length TCPTP because of ease of exp-
ression and purification. These proteins were expressed in
bacteria and purified by ion-exchange chromatography as des-
cribed previously [23]. The CDK/cyclin proteins were prepared
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and purified as described previously [28]. Phosphorylations were
undertaken in CDK assay buffer (20 mM Hepes, pH 7.0, 1 mM
DTT, 10 mM MgCl2, 10 mM NaF, 1 mM sodium vanadate and
10 mM β-glycerophosphate) in the presence of 100 µM ATP
(plus 5 µCi of [γ -32P]ATP) with or without 10 µg of TCPTP-
(1–349) or TCPTP-(1–349)S304E, in the presence or absence of
15 units of the indicated CDK/cyclin proteins, in a total volume
of 30 µl for 30 min at 37 ◦C {1 unit is defined as 1 pmol of
phosphate transferred/min per µg of glutathione S-transferase–
pRb-(773–928) substrate at 37 ◦C [28]}. Reactions were ter-
minated by the addition of 15 µl of 3 × Laemmli sample buffer,
boiled for 5 min and then resolved by SDS/PAGE and analysed
by Coomassie Blue staining and autoradiography.
Polo-like kinase Plk1 assays
Aliquots of 5 µg of dephosphorylated α-casein (Sigma) or 7 µg
of TC45-(1–349) or TC45-(1–349)S304E were incubated with
0.75 µg of purified recombinant Plk1 in kinase buffer (50 mM
Tris, pH 7.7, 10 mM MgCl2, 2 mM EGTA, 5 mM DTT,
0.5 mM sodium vanadate, 5 mM NaF and 0.1 µM okadaic acid)
in the presence of 25 µM ATP (plus 10 µM [γ -32P]ATP) with
or without 50 µM roscovitine in a total volume of 40 µl for
30 min at 30 ◦C. Reactions were terminated by the addition of
20 µl of hot 3 × Laemmli sample buffer, boiled for 5 min and
then resolved by SDS/PAGE and analysed by Coomassie Blue
staining and autoradiography.
PTP assays
HEK293 cells were electroporated as described previously [15]
with 5 µg of TC45-R222M-pCG, TC45-pCG or TC45-S304A-
pCG, and at 24 h post-transfection cells were treated with 100 ng/
ml nocodazole for an additional 20 h. Cells were then homo-
genized (Dounce homogenizer; 20 strokes) in ice-cold hypotonic
lysis buffer (20 mM Tris, pH 7.5, 5 mM KCl, 1.5 mM MgCl2,
2 mM EGTA, 5 µg/ml leupeptin, 1 µg/ml pepstatin, 1 mM benz-
amidine, 2 mM PMSF, 1 µM okadaic acid and 50 nM calyculin A)
and clarified by centrifugation (100000 g, 20 min, 4 ◦C). DTT
was added to the supernatants to a final concentration of 1 mM
before PTP activity was assayed. RCML (reduced carboxyamido-
methylated and maleylated lysozyme) or MBP (myelin basic pro-
tein) was phosphorylated with the baculovirally expressed protein
tyrosine kinase domain of the human insulin receptor [29]. PTP
activity was measured as described previously [23] using 10–
20 µM tyrosine-phosphorylated 32P-labelled RCML or MBP at
30 ◦C for 10–20 min in reaction buffer containing 25 mM im-
idazole, pH 7.2, 5 mM EDTA, 1 mM DTT and 1 mg/ml BSA. No
more than 10–20% of the substrate was dephosphorylated in each
reaction.
RESULTS
Identification of TCPTP phosphorylation sites
Previous studies have indicated that TCPTP can be phosphory-
lated in a cellular context [30]. To identify phosphorylation
sites on TCPTP, asynchronous COS1 cells overexpressing TC45
were labelled with [32P]Pi for 5 h. The overexpressed and 32P-
labelled TC45 was immunoprecipitated, resolved by SDS/PAGE
and digested in situ with trypsin. The 32P-labelled tryptic phos-
phopeptides were then extracted from the polyacrylamide gel,
achieving approx. 98% recovery of 32P. First, the extracted
[32P]phosphopeptides were separated in two dimensions by
high-voltage electrophoresis and TLC, revealing two apparently
distinct phosphopeptides (A and B) (Figure 1A). When the
two phosphopeptides were extracted from the cellulose plates
and analysed for their phosphoamino acid content, both con-
tained 32P-labelled phosphoserine (Figure 1B); 32P-labelled
phosphothreonine and phosphotyrosine were not detected even
in total TC45 tryptic digests (results not shown). These results
indicate that TC45 may be phosphorylated exclusively on serine
in asynchronous cells.
Next, the extracted [32P]phosphopeptides were purified by
reverse-phase chromatography, and [32P]phosphopeptide-conta-
ining fractions were identified by Cerenkov counting (Figure 1C).
Fractions 33 and 37 contained [32P]phosphopeptides and were
analysed further. First, these fractions were subjected to phos-
phopeptide mapping followed by phosphoamino acid analysis.
Based on phosphopeptide mapping, fractions 33 and 37 were
homogeneous and their separation was consistent with the separ-
ation of [32P]phosphopeptides A and B (Figure 1A) respectively
(results not shown). In addition, fractions 33 and 37 contained
only phosphoserine (results not shown). Thus the 32P-labelled
phosphopeptides in fractions 33 and 37 may correspond to the
TC45 tryptic [32P]phosphopeptides A and B in Figure 1(A). Next,
fractions 33 and 37 were analysed by MALDI-TOF MS (Fig-
ure 1D). Peptides phosphorylated on a single site differ from their
dephosphorylated counterparts by 80 mass units (corresponding to
phosphate). We found that in fractions 33 and 34 a pair of peptides
at masses of 1537.81 and 1455.46 were detected that corresponded
to the phosphorylated and dephosphorylated forms of the
theoretical tryptic peptide E295DLSPAFDHSPNK307 (predicted
mass of 1457.54). In fraction 37, a pair of peaks at 1915.37
and 1994.69 differed by approx. 80 mass units and corresponded
to the dephosphorylated and phosphorylated forms of the peptide
E291LSKEDLSPAFDHSPNK307 (predicted mass of 1914.06).
These results indicate that the phosphopeptides in fractions 33
and 37 may represent the same phosphorylation site(s) with
E291LSK295EDLSPAFDHSPNK307 arising from incomplete tryptic
digestion. Two possible phosphorylation sites, corresponding to
Ser-298 and Ser-304, are present in the E295DLSPAFDHSPNK307
tryptic peptide. Phosphate release sequencing of the E295DLSPA-
FDHSPNK307 [32P]phosphopeptide revealed phosphorylation in
the tenth cycle (Figure 1E), consistent with phosphorylation of
Ser-304.
Our results indicated that, in asynchronous COS1 cells, ecto-
pically expressed TC45 was phosphorylated on Ser-304. To
determine the extent of Ser-304 phosphorylation relative to other
potential TC45 phosphorylation sites, Ser-304 was mutated to
alanine (TC45-S304A) and the phosphorylation state of TC45-
S304A was compared with that of wild-type TC45 (Figure 2).
COS1 cells expressing TC45 or TC45-S304A transiently were
labelled with [32P]Pi, and incorporation into immunoprecipitated
TC45 and TC45-S304A was monitored by autoradiography.
Mutation of Ser-304 inhibited the phosphorylation of TC45 in
asynchronous cells by as much as 90% (Figure 2). In contrast,
mutation of Ser-298 to Ala had no significant effect on 32P incor-
poration into TC45 (results not shown). These results indicate
that ectopic TC45 is phosphorylated predominantly on Ser-304 in
asynchronous cells.
Endogenous TC45, but not TC48, is phosphorylated on Ser-304
Since the Ser-304 phosphorylation site was identified using ecto-
pic TC45, we could not exclude the possibility that phosphory-
lation may have occurred due to TC45 overexpression. To assess
the phosphorylation of endogenous TCPTP on Ser-304, we im-
munoprecipitated endogenous TCPTP from COS1 cells transfec-
ted with the pMT2 vector control using the anti-TCPTP anti-
body CF4 (Figure 3A); we also immunoprecipitated TCPTP from
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Figure 1 Identification of TC45 phosphorylation sites
TC45 was overexpressed transiently in asynchronous COS1 cells and labelled for 5 h with 1 mCi of [32P]Pi per 10 cm dish. Radiolabelled TC45 was immunoprecipitated, resolved by SDS/PAGE
and digested in situ with trypsin, and 32P-labelled peptides were extracted as described in the Materials and methods section. More than 98 % of radioactivity was recovered from the gel.
(A) [32P]Phosphopeptide map of TC45 from in-gel tryptic digests, with + marking the origin. HVE, high-voltage electrophoresis. (B) [32P]Phosphopeptides A and B from the phosphopeptide map
were extracted and subjected to phosphoamino acid analysis and visualized by autoradiography (+ marks the origin). Unlabelled phosphoserine (pSer), phosphothreonine (pThr) and phosphotyrosine
(pTyr) standards were run both individually and in combination as internal standards for the [32P]phosphopeptide samples A and B. Shown is the autoradiograph overlaid with the migration of
phosphoamino acid standards (dotted circles) that were visualized by ninhydrin staining. (C) [32P]Phosphopeptides isolated from in-gel tryptic digests were separated by reverse-phase HPLC. The
fractions were collected and radioactivity monitored by Cerenkov counting. (D) The masses of the [32P]phosphopeptides separated by reverse-phase HPLC were determined by MALDI-TOF MS. The top
two panels identify the phosphopeptide in reverse-phase HPLC fraction 33. Phosphopeptide and dephosphopeptide pairs differing by approx. 80 mass units are indicated, as are the corresponding
amino acid sequences. (E) The phosphopeptide present in fraction 33 (E295DLSPAFDHSPNK307) was covalently attached on to a Sequelon-AATM (PerSeptive Biosystems) membrane and subjected
to phosphate-release sequencing on a Hewlett Packard protein sequencer as described in the Materials and methods section. Radiolabelled PTC-amino acids in fractions were monitored by spotting
on to a silica plate followed by PhosphorImager analysis and quantified using Image-Quant software (Molecular Dynamics).
TC45- and TC45-S304A-overexpressing cells using the same
antibody to serve as immunoblot controls for the Ser-304 phos-
phorylation-specific antibody (Figure 3A). The TCPTP immuno-
prepitates were divided in two, resolved by SDS/PAGE and
immunoblotted either with affinity-purified polyclonal anti-
bodies specific for TCPTP phosphorylated on Ser-304 (see
Supplementary Figure 1 at http://www.BiochemJ.org/bj/380/
bj3800939add.htm) or with affinity-purified polyclonal anti-
TCPTP 159 antibodies (see Supplementary Figure 1) (Fig-
ure 3A). Despite endogenous TC48 and TC45 being present
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Figure 2 Ser-304 is the major site of phosphorylation on TC45
COS1 cells were transfected with constructs for the expression of TC45 or TC45-S304A.
Transfected COS1 cells were labelled with [32P]Pi (2 h with 1 mCi/10 cm dish), and radiolabelled
TCPTP was immunoprecipitated, resolved by SDS/PAGE and analysed by Coomassie Blue
staining. 32P incorporation into the immunoprecipitated TC45 or the TC45-S304A mutant
was monitored on a Phosphorimager and quantified using Image-Quant software (Molecular
Dynamics). 32P incorporation was normalized for TCPTP protein and expressed as percentage
incorporation compared with wild-type TC45.
Figure 3 TC45, but not TC48, is phosphorylated on Ser-304
(A) COS1 cells were transfected with the pMT2 vector control or constructs for the expression of
TC45 or the TC45-S304A mutant. TCPTP immunoprecipitates were resolved by SDS/PAGE
and immunoblotted with affinity-purified polyclonal antibodies specific for the TCPTP
phosphorylated on Ser-304 (Phos-TCPTP) or affinity-purified polyclonal TCPTP 159 antibodies
(see Supplementary Figure 1 at http://www.BiochemJ.org/bj/380/bj3800939add.htm). Indicated
are the endogenous TC48 and TC45 proteins in the vector control immunoprecipitates.
(B) COS1 cells were transfected using the calcium phosphate precipitation method as described
previously [14] with 200 ng of pMT2 vector control, TC45-pMT2 or TC48-pMT2. At 24 h
post-transfection, cells were collected in 3 × Laemmli sample buffer and lysates were resolved
by SDS/PAGE and immunoblotted with the monoclonal anti-TCPTP antibody CF4, and then
reprobed with polyclonal Phos-TCPTP antibodies.
in equal amounts in immunoprecipitates from vector control-
transfected cells, only endogenous TC45 was phosphorylated to
any appreciable extent on Ser-304 (Figure 3A). Consistent with
this, TC48 was phosphorylated poorly in comparison with TC45
when low amounts of the TCPTP variants were overexpressed
in COS1 cells (Figure 3B). These results demonstrate (1) that
phosphorylation of Ser-304 is not an artefact of overexpression,
but instead that Ser-304 phosphorylation may be a physiologically
relevant event, and (2) that phosphorylation of Ser-304 may be
specific to TC45 in vivo.
Phosphorylation of TC45 occurs in a cell cycle-dependent
manner and is optimal in mitosis
We next examined the circumstances under which Ser-304 phos-
phorylation may occur. We found that diverse stress-inducing
agents, such as hyperosmotic shock (600 mM, 30 min), cold shock
(18 ◦C, 2 h), heat (42 ◦C, 30 min), oxidative stress (5 mM H2O2,
30 min) and anisomycin (100 µg/ml, 30 min), as well mitogens
such as EGF (100 ng/ml, 5–30 min) and FBS (20%, v/v; 30 min),
had no significant effect on Ser-304 phosphorylation (results
not shown). Similarly, treatment of cells for up to 60 min
with the microtubule-disrupting agent nocodazole (500 ng/ml),
a potent activator of stress-response pathways, had no signi-
ficant effect on Ser-304 phosphorylation (results not shown).
In contrast, treatment of TC45-overexpressing HEK293 cells for
prolonged periods of time (16–20 h) with nocodazole (200 ng/
ml), so that cells were arrested in mitosis (Figure 4A, left panel),
caused a significant increase in Ser-304 phosphorylation and
retarded the electrophoretic mobility of TC45 (Figure 4A, right
panel; see also Supplementary Figure 1 at http://www.BiochemJ.
org/bj/380/bj3800939add.htm). A similar increase in the phos-
phorylation of Ser-304 was observed when cells were arrested in
mitosis with the microtubule-stabilizing agent colcemid (results
not shown). These results indicate that Ser-304 phosphorylation
may be cell cycle-dependent.
To examine further the phosphorylation status of Ser-304 during
cell cycle progression, CV1 cells expressing ectopic TC45 were
accumulated at the G1/S transition (thymidine block) and released
into G2, mitosis (M) and subsequently G1 of the next cell cycle
(Figure 4B). Cell cycle progression was monitored by assessing
DNA content as measured by FACS and by assessing cyclin B1
protein levels; cyclin B1 levels are low in G1, then increase in
G2, peaking at metaphase of mitosis; the protein is degraded at
anaphase of mitosis, when sister chromatids segregate and cell
division ensues [31]. Between 5 and 7 h after release from the
G1/S block, the majority of cells had a 4n DNA content and
increased expression of cyclin B1, consistent with cells being in
late G2 or M phase (Figure 4B). After 8 h of release, the proportion
of cells with a 4n DNA content had declined, coinciding with a
dramatic loss of cyclin B1 protein, consistent with cells exiting
mitosis (Figure 4B). Ser-304 phosphorylation was low for the
first 6 h, but increased dramatically at 7 h (Figure 4B). This delay
in phosphorylation relative to the increase in cells with 4n DNA
and cyclin B1 protein indicates that Ser-304 phosphorylation may
occur late in G2 and in mitosis. Ser-304 phosphorylation declined
at 8 h, correlating with cyclin B1 loss and mitotic exit (Fig-
ure 4B). Consistent with these results, fluorescence microscopy of
asynchronous HEK293 cells expressing ectopic TC45 indicated
that Ser-304 phosphorylation was optimal in mitotic cells, but
absent in cells undergoing cytokinesis (Figure 4C).
Finally, to assess whether Ser-304 phosphorylation may occur
in late G2 prior to the onset of mitosis, HEK293 cells expressing
TC45 or the TC45-S304A mutant as a control were treated with
the DNA double-strand-break-inducing agent adriamycin, which
arrests cells at the G2/M checkpoint by activating the ATR (ataxia
telangiectasia-related)/Chk1 protein kinase signalling cascade
[32]. The phosphorylation state of TC45 in response to adriamycin
was monitored by assessing the electrophoretic mobility of TC45
and comparing it with that of TC45 in asynchronous cells or
cells arrested in mitosis by overnight treatment with nocodazole
(Figure 5). Treatment of HEK293 cells with adriamycin resulted
in the accumulation of a G2/M cell population (4n DNA
content), consistent with G2/M checkpoint activation (Figure 5A,
upper panels), but did not alter the electrophoretic mobility
of TC45 significantly when compared with asynchronous cells
(Figure 5A, lower panels). In contrast, nocodazole caused
an increase in electrophoretically retarded (Figure 5A, lower
panels) and phosphorylated (see Supplementary Figure 1 at
http://www.BiochemJ.org/bj/380/bj3800939add.htm) TC45. To
assess further whether Ser-304 phosphorylation may occur at
the G2/M checkpoint, we compared Ser-304 phosphorylation in
cells accumulated at G1/S (thymidine block) with that in cells
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Figure 4 Phosphorylation of Ser-304 is cell cycle-dependent and optimal
in mitosis
(A) HEK293 cells were transfected with TC45-pCG for the expression of TC45. At 24 h post-
transfection, cells were left untreated or treated for 20 h with 200 ng/ml nocodazole. Left panel:
cells were fixed and DNA content (horizontal access) was measured by propidium iodide staining
and FACS. Cells with 2n (G1) and 4n (G2/M) DNA contents are indicated. Right panel: cells were
collected in hot 3 × Laemmli sample buffer containing 6 % (v/v) 2-mercaptoethanol, resolved
extensively by SDS/PAGE (16 cm long gels; see the Materials and methods section) and
immunoblotted with affinity-purified polyclonal antibodies specific for TC45 phosphorylated on
Ser-304 (Phos-TC45) or the monoclonal anti-TCPTP antibody CF4. The retarded electrophoretic
mobility of TC45 in response to the nocodazole block is indicated by arrows. (B) CV1 cells
were electroporated with constructs for the expression of TC45. At 24 h post-transfection,
cells were arrested at G1/S with 2 mM thymidine and then released in DMEM plus 10 % (v/v)
FBS for the indicated times. Cells were collected in 3 × Laemmli sample buffer containing
6 % (v/v) 2-mercaptoethanol, resolved by SDS/PAGE and immunoblotted with Phos-TC45,
TC45 (CF4), anti-(cyclin B1) or anti-actin antibodies. Alternatively, cells were fixed and DNA
content was measured by propidium iodide staining and FACS, and cells in G1, S and G2/M
were quantified using CellQuest (Becton Dickinson) software. (C) Asynchronous HEK293 cells
overexpressing TC45 were processed for immunofluorescence microscopy with Phos-TC45 and
TC45 (CF4) antibodies. Cells consistent with a mitotic (identified by their rounded morphology
with diffuse TC45 staining due to disruption of nuclear envelope) or cytokinetic phenotype are
indicated.
that had been released for 4, 7 or 12 h, or otherwise released for
4 h and then treated for another 12 h with adriamycin to arrest
cells at the G2/M checkpoint (Figure 5B). Consistent with the
results in Figures 4 and 5(A), Ser-304 phosphorylation increased
significantly in mitotic cells 7 h after release from G1/S, but not
in cells arrested at the G2/M checkpoint with adriamycin (Fig-
ure 5B). Taken together, these results indicate that TC45 Ser-304
phosphorylation may be restricted to the mitotic phase of the cell
cycle.
Figure 5 Phosphorylation of Ser-304 is not induced upon G2/M checkpoint
arrest with adriamycin
(A) HEK293 cells were transfected with 5 µg of pCG vector control or constructs for the
expression of TC45 or TC45-S304A (S304A). At 24 h post-transfection, cells were left untreated
or treated for 20 h with 100 ng/ml nocodazole or 1 µM adriamycin. Upper panels: TC45-pCG-
transfected cells were fixed and DNA content measured by propidium iodide staining and FACS.
Cells with 2n (G1) and 4n (G2/M) DNA contents are indicated. Lower panels: cells were collected
in hot 3 × Laemmli sample buffer containing 6 % (v/v) 2-mercaptoethanol, resolved extensively
on SDS/PAGE (16 cm long gels; see the Materials and methods section) and immunoblotted with
anti-TCPTP antibody CF4 to detect TC45. The electrophoretic mobilities of the dephosphorylated
and phosphorylated forms of TC45 are indicated. (B) HEK293 cells were transfected with 100 ng
of pCG vector control or constructs for the expression of TC45 or TC45-S304A (S304A). At
20 h post-transfection, cells were accumulated at G1/S with 2 mM thymidine (Thy) and then
released in DMEM plus 10 % (v/v) FBS for the indicated times, or otherwise released for 4 h and
then treated with 1 µM adriamycin for an additional 12 h. Upper panels: TC45-pCG transfected
cells were analysed by FACS as indicated above. Lower panels: cells were collected, resolved
by SDS/PAGE and immunoblotted with antibodies specific for TC45 phosphorylated on Ser-304
(Phos-TC45), total TC45 (CF4) or actin.
Phosphorylation of Ser-304 does not modulate TC45 activity
Previous studies have shown that the non-catalytic C-terminus
of TC45 can suppress TC45 activity through a yet to be defined
autoinhibitory mechanism [23]. Phosphorylation of Ser-304 may
alter intrasteric interactions to modulate TC45 activity [23]. To
ascertain whether this might be the case, we examined first
whether the phosphatase activity of TC45 was increased in
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Figure 6 Phosphorylation of Ser-304 does not alter the phosphatase activity
of TC45
(A) HEK293 cells were transfected with constructs for the expression of a phosphatase-
dead TC45-R222M control or wild-type TC45 (WT). At 24 h post-transfection, cells were
left untreated or treated for 20 h with 100 ng/ml nocodazole (Noc). (B) HEK293 cells transfected
with constructs for the expression of TC45-R222M, wild-type TC45 (Wt) or TC45-S304A
were treated with 100 ng/ml Noc for 20 h. Cells in (A) and (B) were homogenized in
hypotonic lysis buffer and clarified by centrifugation as described in the Materials and methods
section. PTP activity in supernatants was measured using tyrosine-phosphorylated 32P-labelled
MBP as substrate. The experiments shown are representative of at least three independent
experiments with triplicate transfections assayed in duplicate. PTP activity was normalized for
the overexpressed TCPTP protein in the corresponding supernatants. In (B), a representative
immunoblot of supernatants from wild-type TC45- or TC45-S304A-expressing cells that were
resolved extensively by SDS/PAGE (16 cm long gels; see the Materials and methods section)
is shown; the electrophoretic mobilities of the phosphorylated and dephosphorylated forms of
TC45 are indicated.
mitotic cells (Figure 6) where Ser-304 phosphorylation was
optimal (Figure 4). We measured PTP activity in lysates from
HEK293 cells transfected with constructs for the expression
of wild-type TC45 or the catalytically inactive TC45-R222M
mutant (Figure 6A). Asynchronous cells or nocodazole-treated
metaphase-arrested cells were homogenized in hypotonic lysis
buffer and PTP activity measured using tyrosine-phosphorylated
RCML (results not shown) or MBP (Figure 6A) as substrate.
We found no significant difference in TC45 activity in lysates
from metaphase-arrested cells where TC45 was largely phos-
phorylated, as compared with asynchronous cells where TC45
was predominantly dephosphorylated (Figure 6A). Next, we com-
pared the activity of TC45 with that of the S304A mutant from
nocodazole-treated metaphase-arrested cells (Figure 6B). Muta-
tion of Ser-304 and ablation of phosphorylation had no signi-
ficant effect on phosphatase activity (Figure 6B) under conditions
where phosphorylation of wild-type TC45, as determined by its
retarded electrophoretic mobility relative to TC45-S304A (see
Supplementary Figure 1), was stoichiometric (Figure 6B, inset).
Taken together, these results indicate that phosphorylation of
Ser-304 may not alter the phosphatase activity of TC45.
Phosphorylation of Ser-304 is mediated by CDKs
The Ser-304 phosphorylation site of TC45 is followed immedi-
ately by a proline residue (AFDHS304P) and conforms to the
consensus recognition sequence for two classes of protein kinases:
the MAPKs (mitogen-activated protein kinases) and the CDKs.
In addition, the Ser-304 site (AFDHS304P) may also conform to
the consensus site for phosphorylation by the Polo-like kinase
Plk1 ([E/D]X[S/T]) [33]. All three protein kinases are essential
for mitotic progression [34–37]. Since a variety of cellular
stresses failed to modulate the phosphorylation status of Ser-304
(results not shown), we surmised that stress-activated MAPKs
such as c-Jun N-terminal kinase and p38 were unlikely to
phosphorylate Ser-304. To examine the possible contribution
of the MAPKs ERK1/2 to Ser-304 phosphorylation, TC45-
expressing COS1 cells were treated with PD98059, a specific
pharmacological inhibitor of ERK1/2 activation. Although
PD98059 inhibited completely the activation of ERK1/2, it had
no effect on TC45 Ser-304 phosphorylation, even after overnight
treatment (Figure 7A). These results demonstrate that Ser-304
phosphorylation is independent of ERK1/2 activity.
To examine whether the phosphorylation of Ser-304 may be
mediated by CDKs, TC45-expressing HEK293 cells were treated
with roscovitine, a specific pharmacological inhibitor of CDKs
1, 2 and 5 (inhibits mammalian cellular proliferation with an
average IC50 of 16 µM) [38]. Treatment with roscovitine inhi-
bited almost completely the phosphorylation of Ser-304 (Fig-
ure 7B). Furthermore, treatment of TC45-overexpressing cells
with another specific CDK inhibitor, SU9516 (inhibits G2/M
progression at concentrations of approx. 12.5–25 µM) [39], also
suppressed Ser-304 phosphorylation (Figure 7C). Taken together,
these results indicate that CDKs may phosphorylate TC45
in vivo. Consistent with this, we found that recombinant CDKs
could phosphorylate the Ser-304 site directly in vitro (Figure 8A).
Although, the recombinant CDKs could also phosphorylate other
site(s) on TCPTP-(1–349), the stoichiometry of these in vitro
phosphorylation events was significantly lower (Figure 8A). In
contrast, Plk1 activity was not inhibited by roscovitine in vitro,
indicating that Plk1 is unlikely to phosphorylate Ser-304 in vivo.
Moreover, Plk1 could not phosphorylate TCPTP either on
Ser-304 or on other sites under conditions where phosphorylation
of the heterologous substrate α-casein was robust (Figure 8B).
Taken together, these results indicate that CDKs may mediate the
phosphorylation of TC45 on Ser-304 in vivo.
DISCUSSION
Mitosis is morphologically the most dynamic phase of the cell
cycle, and a large number of events are co-ordinated temporally
and spatially by reversible protein phosphorylation [31,34].
In the present study we have identified Ser-304 as a major
phosphorylation site in the ubiquitous tyrosine phosphatase
TCPTP. We have generated phosphorylation-specific antibodies
and demonstrated that Ser-304 phosphorylation occurs in mito-
sis and is mediated by CDKs.
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Figure 7 Phosphorylation of Ser-304 is inhibited by the CDK inhibitors
roscovitine and SU9516, but not by the MEK (MAPK/ERK kinase) inhibitor
PD98059
(A) COS1 cells were transfected with constructs for the expression of TC45. Cells were treated
with 50 µM PD98059 for the inhibition of ERK1/2 for 4 or 20 h as indicated. Cells were
collected in hot 3 × Laemmli sample buffer containing 6 % (v/v) 2-mercaptoethanol, resolved
by SDS/PAGE and immunoblotted with polyclonal antibodies specific for phosphorylated
and activated ERK1/2 (Phos-ERK1/2), or for TCPTP phosphorylated on Ser-304 to detect
phosphorylated TC45 (Phos-TC45). Immunoblots were re-probed with the anti-ERK2 antibody
1B3B9 or the anti-TCPTP antibody CF4 to detect ERK2 and TC45 respectively. (B) HEK293 cells
were transfected with constructs for the expression of TC45. Cells were treated with vehicle
alone or 55 µM roscovitine for 20 h. Cells then were collected in hot 3 × Laemmli sample
buffer containing 6 % (v/v) 2-mercaptoethanol, resolved by SDS/PAGE and immunoblotted with
Phos-TC45 or TC45 CF4 antibodies. (C) HEK293 cells were transfected with constructs for the
expression of TC45 or TC45-S304A and treated with vehicle alone or the indicated concentrations
of SU9516 for 20 h. Cells were collected, resolved by SDS/PAGE and immunoblotted with Phos-
TC45 or TC45 (CF4) antibodies.
CDKs phosphorylate a wide array of substrates regulating cell
cycle progression [31,34,40]. Different CDKs act to regulate
different stages of the cell cycle, with CDK4/cyclin D activity
being optimal in G1, CDK2/cyclin E at the G1/S transition,
CDK2/cyclin A at the G2/M transition and CDK1/cyclin B1 in
mitosis [31,34]. Although all CDKs tested phosphorylated Ser-
304 efficiently in vitro, phosphorylation of Ser-304 was optimal
as cells progressed into mitosis, and subsided upon mitotic exit,
consistent with phosphorylation being mediated by either CDK1/
cyclin B1 or CDK2/cyclin A in vivo. Whereas CDK2/cyclin
Figure 8 CDKs, but not Plk1, phosphorylate Ser-304 in vitro
(A) Recombinant TCPTP-(1–349) (WT) or TCPTP-(1–349)S304E (S304E) proteins were
phosphorylated with the indicated CDK/cyclin proteins prepared and purified as described
previously [28] in the presence of 100 µM ATP (plus 5 µCi of [γ -32P]ATP) as described in
the Materials and methods section. Reactions were terminated by the addition of 3 × Laemmli
sample buffer, and resolved by SDS/PAGE and analysed by Coomassie Blue staining and
autoradiography. (B) Recombinant TCPTP-(1–349) (Wt) or TCPTP-(1–349)S304E proteins or
dephosphorylated α-casein were incubated with purified recombinant Plk1 in the presence of
25 µM ATP (plus 10 µM [γ -32P]ATP) with or without 50 µM roscovitine (Rosc) for 30 min at
30 ◦C. Reactions were terminated by the addition of 3 × Laemmli sample buffer, and resolved
by SDS/PAGE and analysed by Coomassie Blue staining and autoradiography. Indicated are
casein, Plk1 and the TCPTP proteins.
A is important for S-phase progression and the G2/M transition,
CDK1/cyclin B1 is essential for mitotic entry and regulates mitotic
processes such as nuclear envelope breakdown, centrosome separ-
ation, spindle assembly, chromosome separation and mitotic exit
[34]. CDK2/cyclin A activity increases steadily from S phase and
peaks at the G2/M transition, but decreases as cells proceed into
mitosis. In contrast, CDK1/cyclin B is activated at the G2/M tran-
sition and peaks in mitosis [31,34], but induction of the G2/M
checkpoint prevents CDK1 activation and mitotic entry [31,34].
Since Ser-304 phosphorylation did not occur in response to G2/M
checkpoint activation by adriamycin, our studies indicate that
Ser-304 may be phosphorylated by CDK1/cyclin-B1 in vivo.
Whereas the phosphorylation of dual-specificity Cdc25 phos-
phatases by CDKs to regulate mitotic progression is well
documented [41,42], evidence for phosphorylation of tyrosine-
specific PTPs by CDKs in vivo has been somewhat scant. TCPTP
and PTP1B are highly related phosphatases and share an overall
sequence identity of 65% (72% identity and 86% similarity
within the catalytic domain) [1]. PTP1B is phosphorylated in
mitosis on two Ser-Pro sites [43] that are not present in TCPTP.
Only one of these two PTP1B Ser-Pro sites can serve as an efficient
site for phosphorylation by CDKs in vitro [43]. Moreover, the
phosphorylation of PTP1B on both sites also occurs in response
to cellular stresses, in particular osmotic shock, independent
of cell cycle stage and MAPK activation [44]. In contrast,
phosphorylation of TCPTP on Ser-304 was not induced by cellular
stresses such as osmotic shock, indicating that TCPTP and PTP1B
may be phosphorylated by distinct protein kinases in vivo.
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In contrast with the Cdc25 phosphatases, where phosphory-
lation on different sites by CDKs and other protein kinases can
regulate subcellular localization and activity [31,41,42,45], phos-
phorylation of TCPTP on Ser-304 had no apparent effect
on TC45 activity. In addition, we observed no apparent role
for Ser-304 phosphorylation in controlling TC45 localization
(see Supplementary Figure 2 at http://www.BiochemJ.org/bj/
380/bj3800939add.htm). Mutation of Ser-304 to alanine or
glutamic acid did not alter the nucleocytoplasmic distribution
of TC45 in response to mitogens such as EGF or to cellular
stresses such as hyperosmotic shock (results not shown) that
induce the cytoplasmic accumulation of TC45 [12], and we
observed no significant difference in localization in G1, G2
or mitotic cells (see Supplementary Figure 2). In addition, in
mitotic cells, where Ser-304 phosphorylation was optimal, the
localization of TC45 phosphorylated on Ser-304, as monitored
with our phosphorylation-specific antibodies, was similar to
that of total TC45 monitored with the monoclonal anti-TCPTP
antibody CF4 (results not shown). Furthermore, when nuclei
from TC45-overexpressing HeLa cells were fractionated into
soluble, chromatin and nuclear matrix-associated proteins, TC45
was detected in the soluble and nuclear matrix fractions, but
not in chromatin fractions, and mutation of Ser-304 to Ala had
no significant effect on this distribution (results not shown).
Similarly, phosphorylation of Ser-304 did not alter TC45 protein
stability, as assessed by [35S]methionine pulse–chase experiments
comparing wild-type TC45 and the Ser-304 phosphorylation site
mutants (see Supplementary Figure 2). In the case of Cdc25,
a recent paper by Bulavin et al. [42] has shown that dual
phosphorylation of Ser-214 and Ser-216 controls localization
and mitotic progression. Whereas phosphorylation of Cdc25C
on Ser-216 allows for 14-13-3 binding and nuclear exclusion,
preventing CDK1 activation prior to mitosis, phosphorylation
on Ser-214 prevents phosphorylation on Ser-216 and 14-13-
3 binding, making cells unresponsive to DNA damage and
ensuring that CDK1 remains active once mitosis is initiated [42].
Our studies indicate that the Ser-304 site is the major site of
phosphorylation in human TCPTP in randomly growing cells,
and the major site of CDK-mediated phosphorylation in vitro.
However, we cannot exclude the possibility that other steady-
state phosphorylation sites may exist, or that other sites may be
phosphorylated in response to specific stimuli, and that, together
with Ser-304 phosphorylation, these may regulate TC45. In
line with this possibility, we observed low levels of 32P incor-
poration in the TC45-S304A mutant, but the physiological
significance of such low-level incorporation in overexpressed
TC45 remains unclear.
Although the Ser-304 site is conserved in the porcine orthologue
of human TCPTP, rats lack the sequence corresponding to
residues 296–314 and mice lack the proline residue immediately
following Ser-304 [4]. Therefore the Ser-304 CDK site is not
conserved in rodents. However, it is possible that other sites may
be phosphorylated in place of Ser-304; consistent with this, a
previous study has reported that rat TCPTP is phosphorylated in
mitosis on a yet to be identified site, and that this phosphorylation
event retards TC45’s electrophoretic mobility [30]. Hence the
functional outcome of phosphorylation on Ser-304 of human
TCPTP in mitosis might be conserved in different species.
A recent study from the laboratory of David Shalloway [46] has
indicated that PTPα-mediated c-Src activation in mitosis is regu-
lated by protein kinase C-dependent phosphorylation of PTPα.
Whereas the catalytic activity of PTPα towards non-specific
substrates such as tyrosine-phosphorylated MBP is suppressed
only slightly when the protein kinase C phosphorylation sites
are mutated to Ala, activity towards the physiological substrate
c-Src is abrogated completely, demonstrating that Ser/Thr
phosphorylation of a PTP can regulate substrate specificity [46].
Therefore, although mutating Ser-304 to Ala had no significant
effect on TC45 activity towards non-physiological substrates such
as tyrosine-phosphorylated RCML and MBP, we cannot exclude
the possibility that Ser-304 phosphorylation may regulate activity
towards a physiologically relevant mitotic substrate. Although
very early studies on TCPTP had indicated that expression of
the TCPTP catalytic domain in baby hamster kidney cell lines
could induce cytokinetic failure and multinucleation [47], mitotic
substrates for TCPTP remain unknown.
In the present study we have observed differential mitotic phos-
phorylation of human TC48 and TC45 on Ser-304, suggesting
that the TCPTP variants might have distinct functions during
cell division. Our studies identify Ser-304 as a major TCPTP
phosphorylation site and the TC45 variant as a potential mediator
of CDK1/cyclin B1 processes in mitosis.
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